Techniclone to Obtain License for Antibody

Techniclone Corp. said Thursday that it will exercise its option to obtain the license for an anti-angiogenesis antibody, 2C3, and its derivatives from the University of Texas Southwestern Medical Center in Dallas.

The Tustin biopharmaceutical company, which develops cancer treatments, said in a press release that the antibody can inhibit tumor vessel growth.

Techniclone will obtain all the antibody rights and pay all patent costs, completing the license agreement with the university.